Literature DB >> 24484199

Synthesis of bufalin derivatives with inhibitory activity against prostate cancer cells.

Xiao-Feng Yuan1, Hai-Yan Tian, Juan Li, Lu Jin, Shu-Tai Jiang, Ken Wing-Keung Liu, Cheng Luo, David A Middleton, Mikael Esmann, Wen-Cai Ye, Ren-Wang Jiang.   

Abstract

Bufalin possesses a strong anti-cancer effect, but the cardiac toxicity targeting the Na(+), K(+)-ATPase limits its application. Here, two bufalin derivatives, bufadienolactam (1) and secobufalinamide (2), were synthesised by treating bufalin with ammonium acetate in dimethylformamide solution. Their structures were elucidated by extensive spectroscopic methods. The structure of compound 2 was further confirmed by single-crystal X-ray diffraction analysis. Compounds 1 and 2 expressed strong inhibitory activities against androgen-dependent prostate cancer cells (IC₅₀ values about 10 μM), but only weak inhibition on Na(+), K(+)-ATPase (Ki about 70 μM), indicating that they might be potential anti-prostate cancer agents without severe cardiac toxicity.

Entities:  

Keywords:  K+-ATPase; Na+; androgen receptor; bufalin; prostate cancer

Mesh:

Substances:

Year:  2014        PMID: 24484199     DOI: 10.1080/14786419.2014.881363

Source DB:  PubMed          Journal:  Nat Prod Res        ISSN: 1478-6419            Impact factor:   2.861


  1 in total

1.  Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway.

Authors:  Jinlin Xie; Wenfeng Lin; Linglong Huang; Naijin Xu; Abai Xu; Binshen Chen; Masami Watanabe; Chunxiao Liu; Peng Huang
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.